Stratasys Releases Third Quarter 2021 Financial Results
Stratasys Ltd. (NASDAQ: SSYS) reported Q3 2021 revenue of $159.0 million, a 24.3% increase from Q3 2020. GAAP net loss stood at $18.1 million, or $0.28 per diluted share, an improvement from a net loss of $405.1 million a year prior. The company secured significant contracts with the US Navy and a major OEM for part manufacturing. Cash from operations was $3.0 million, with $519.9 million in cash reserves and no debt. Stratasys retains a positive outlook, forecasting 16% revenue growth in Q4 2021 compared to the previous year.
- Revenue increased 24.3% year-over-year to $159.0 million.
- Secured two major contracts for end-use part production.
- Achieved a gross margin of 42.9%, up from 38.9% year-over-year.
- Cash from operations improved to $3.0 million.
- Anticipates 16% revenue growth in Q4 2021.
- GAAP net loss of $18.1 million, despite revenue growth.
- Operating expenses expected to rise by approximately $36 million for the full year.
-
Revenue of
$159.0 million -
GAAP net loss of
, or$18.1 million per diluted share, and non-GAAP net income of$0.28 , or$0.5 million per diluted share$0.01 -
Generated
of cash from operations$3.0 million -
Secured two large, end-use part manufacturing contracts with the
US Navy and a leading, global OEM -
cash, cash equivalents and short-term deposits, and no debt at quarter end$519.9 million
Third Quarter 2021 Financial Results Summary Compared to Third Quarter 2020:
-
Revenue of
compared to$159.0 million .$127.9 million -
GAAP gross margin was
42.9% , compared to38.9% . -
Non-GAAP gross margin was
48.2% , compared to46.8% . -
GAAP operating loss was
, compared to an operating loss of$21.9 million .$404.3 million -
Non-GAAP operating income was
, compared to an operating loss of$1.8 million .$1.0 million -
GAAP net loss was
, or$18.1 million per diluted share, compared to a net loss of$0.28 , or$405.1 million per diluted share.$7.35 -
Non-GAAP net income of
, or$0.5 million per diluted share, compared to a net loss of$0.01 , or$3.0 million per diluted share.$0.05 -
Adjusted EBITDA was
, compared to$7.8 million .$5.2 million -
Cash generated from operations of
, compared to$3.0 million .$2.6 million
Dr.
Financial Outlook:
Based on current market conditions and assuming that the impacts related to the pandemic or global supply chain constraints do not impede the economic environment further, the Company is reiterating and updating its outlook as follows:
-
Fourth quarter 2021 revenue approximately
16% higher year-over-year, driven by continued growth in systems relative to Q4 of both 2020 and 2019. -
Full year-operating expenses expected to rise approximately
compared to 2020, primarily due to fully owning$36 million Xaar 3D and higher operating costs associated with higher revenues. -
Full year capital expenditures anticipated to range from
to$24 million .$30 million - Longer term, the Company continues to expect significant leverage benefit from its investments as revenue growth should start to accelerate in 2022 and beyond.
The Company plans to webcast its conference call to discuss its third quarter 2021 financial results on
The investor conference call will be available via live webcast on the Stratasys Web site at investors.stratasys.com, or directly at the following web address: https://78449.themediaframe.com/dataconf/productusers/ssys/mediaframe/47128/indexl.html.
To participate by telephone, the
To learn more about
Cautionary Statement Regarding Forward-Looking Statements
The statements in this press release regarding
Use of Non-GAAP Financial Measures
The non-GAAP data included herein, which excludes certain items as described below, are non-GAAP financial measures. Our management believes that these non-GAAP financial measures are useful information for investors and shareholders of our Company in gauging our results of operations (i) on an ongoing basis after excluding mergers, acquisitions and divestments related expense or gains and reorganization-related charges or gains, legal provisions and (ii) excluding non-cash items such as stock-based compensation expenses, acquired intangible assets amortization, including intangible assets amortization related to equity method investments, impairment of long-lived assets and goodwill, revaluation of our investments and the corresponding tax effect of those items. These non-GAAP adjustments either do not reflect actual cash outlays that impact our liquidity and our financial condition or have a non-recurring impact on the statement of operations, as assessed by management. These non-GAAP financial measures are presented to permit investors to more fully understand how management assesses our performance for internal planning and forecasting purposes. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of our results of operations without including all items indicated above during a period, which may not provide a comparable view of our performance to other companies in our industry. Investors and other readers should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in accordance with GAAP. Reconciliation between results on a GAAP and non-GAAP basis is provided in a table below.
Stratasys Ltd. | ||||||||
Consolidated Balance Sheets | ||||||||
(Unaudited) | ||||||||
(in thousands, except share data) | ||||||||
|
|
|
||||||
2021 |
|
2020 |
||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ |
332,871 |
|
$ |
272,092 |
|
||
Short-term deposits |
|
187,000 |
|
|
27,000 |
|
||
Accounts receivable, net of allowance for credit losses of |
|
121,848 |
|
|
106,068 |
|
||
Inventories |
|
119,925 |
|
|
131,672 |
|
||
Prepaid expenses |
|
8,634 |
|
|
6,717 |
|
||
Other current assets |
|
27,317 |
|
|
16,943 |
|
||
Total current assets |
|
797,595 |
|
|
560,492 |
|
||
Non-current assets | ||||||||
Property, plant and equipment, net |
|
199,668 |
|
|
201,232 |
|
||
|
39,750 |
|
|
35,694 |
|
|||
Other intangible assets, net |
|
117,010 |
|
|
131,569 |
|
||
Operating lease right-of-use assets |
|
15,624 |
|
|
21,298 |
|
||
Other non-current assets |
|
58,365 |
|
|
39,717 |
|
||
Total non-current assets |
|
430,417 |
|
|
429,510 |
|
||
Total assets | $ |
1,228,012 |
|
$ |
990,002 |
|
||
LIABILITIES AND EQUITY | ||||||||
Current liabilities | ||||||||
Accounts payable | $ |
48,292 |
|
$ |
16,987 |
|
||
Accrued expenses and other current liabilities |
|
30,875 |
|
|
31,061 |
|
||
Accrued compensation and related benefits |
|
36,983 |
|
|
25,659 |
|
||
Deferred revenues - short term |
|
49,104 |
|
|
49,165 |
|
||
Operating lease liabilities - short term |
|
7,514 |
|
|
9,282 |
|
||
Total current liabilities |
|
172,768 |
|
|
132,154 |
|
||
Non-current liabilities | ||||||||
Deferred revenues - long term |
|
17,980 |
|
|
14,227 |
|
||
Operating lease liabilities - long term |
|
8,353 |
|
|
12,567 |
|
||
Contingent consideration |
|
40,589 |
|
|
37,400 |
|
||
Other non-current liabilities |
|
37,869 |
|
|
34,059 |
|
||
Total non-current liabilities |
|
104,791 |
|
|
98,253 |
|
||
Total liabilities |
|
277,559 |
|
|
230,407 |
|
||
Redeemable non-controlling interests |
|
- |
|
|
227 |
|
||
Equity | ||||||||
Ordinary shares, |
|
182 |
|
|
155 |
|
||
Additional paid-in capital |
|
3,001,685 |
|
|
2,753,955 |
|
||
Accumulated other comprehensive loss |
|
(8,372 |
) |
|
(8,846 |
) |
||
Accumulated deficit |
|
(2,043,042 |
) |
|
(1,985,896 |
) |
||
Total equity |
|
950,453 |
|
|
759,368 |
|
||
Total liabilities and equity | $ |
1,228,012 |
|
$ |
990,002 |
|
Stratasys Ltd. | ||||||||||||||||
Consolidated Statements of Operations | ||||||||||||||||
(in thousands, except per share data) | ||||||||||||||||
Three Months Ended |
|
Nine Months Ended |
||||||||||||||
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||||
(unaudited) |
|
(unaudited) |
|
(unaudited) |
|
(unaudited) |
||||||||||
Net sales | ||||||||||||||||
Products | $ |
108,888 |
|
$ |
83,548 |
|
$ |
299,517 |
|
$ |
240,597 |
|
||||
Services |
|
50,121 |
|
|
44,344 |
|
|
140,686 |
|
|
137,825 |
|
||||
|
159,009 |
|
|
127,892 |
|
|
440,203 |
|
|
378,422 |
|
|||||
Cost of sales | ||||||||||||||||
Products |
|
54,820 |
|
|
47,339 |
|
|
151,471 |
|
|
126,556 |
|
||||
Services |
|
36,001 |
|
|
30,784 |
|
|
101,697 |
|
|
98,491 |
|
||||
|
90,821 |
|
|
78,123 |
|
|
253,168 |
|
|
225,047 |
|
|||||
Gross profit |
|
68,188 |
|
|
49,769 |
|
|
187,035 |
|
|
153,375 |
|
||||
Operating expenses | ||||||||||||||||
Research and development, net |
|
22,645 |
|
|
19,562 |
|
|
65,683 |
|
|
65,059 |
|
||||
Selling, general and administrative |
|
67,462 |
|
|
48,343 |
|
|
184,353 |
|
|
155,630 |
|
||||
|
- |
|
|
386,154 |
|
|
- |
|
|
386,154 |
|
|||||
|
90,107 |
|
|
454,059 |
|
|
250,036 |
|
|
606,843 |
|
|||||
Operating loss |
|
(21,919 |
) |
|
(404,290 |
) |
|
(63,001 |
) |
|
(453,468 |
) |
||||
Financial expenses, net |
|
(634 |
) |
|
(167 |
) |
|
(1,383 |
) |
|
(847 |
) |
||||
Loss before income taxes |
|
(22,553 |
) |
|
(404,457 |
) |
|
(64,384 |
) |
|
(454,315 |
) |
||||
Income tax benefit |
|
699 |
|
|
343 |
|
|
6,009 |
|
|
2,250 |
|
||||
Share in profit (loss) of associated companies |
|
3,778 |
|
|
(952 |
) |
|
1,229 |
|
|
(2,740 |
) |
||||
Net loss |
|
(18,076 |
) |
|
(405,066 |
) |
|
(57,146 |
) |
|
(454,805 |
) |
||||
Net loss attributable to non-controlling interests |
|
- |
|
|
(4 |
) |
|
- |
|
|
(54 |
) |
||||
Net loss attributable to |
$ |
(18,076 |
) |
$ |
(405,062 |
) |
$ |
(57,146 |
) |
$ |
(454,751 |
) |
||||
Net loss per ordinary share attributable to |
||||||||||||||||
Basic | $ |
(0.28 |
) |
$ |
(7.35 |
) |
$ |
(0.91 |
) |
$ |
(8.29 |
) |
||||
Diluted | $ |
(0.28 |
) |
$ |
(7.35 |
) |
$ |
(0.91 |
) |
$ |
(8.29 |
) |
||||
Weighted average ordinary shares outstanding | ||||||||||||||||
Basic |
|
65,018 |
|
|
55,086 |
|
|
62,888 |
|
|
54,851 |
|
||||
Diluted |
|
65,018 |
|
|
55,086 |
|
|
62,888 |
|
|
54,851 |
|
Three Months Ended |
|||||||||||||||||||||||||
2021 |
|
Non-GAAP |
|
2021 |
|
2020 |
|
Non-GAAP |
|
2020 |
|||||||||||||||
GAAP |
|
Adjustments |
|
Non-GAAP |
|
GAAP |
|
Adjustments |
|
Non-GAAP |
|||||||||||||||
|
|||||||||||||||||||||||||
Gross profit (1) | $ |
68,188 |
|
$ |
8,507 |
|
$ |
76,695 |
$ |
49,769 |
|
$ |
10,036 |
|
$ |
59,805 |
|
||||||||
Operating income (loss) (1,2) |
|
(21,919 |
) |
|
23,739 |
|
|
1,820 |
|
(404,290 |
) |
|
403,268 |
|
|
(1,022 |
) |
||||||||
Net income (loss) attributable to |
|
(18,076 |
) |
|
18,592 |
|
|
516 |
|
(405,061 |
) |
|
402,050 |
|
|
(3,011 |
) |
||||||||
Net income (loss) per diluted share attributable to |
$ |
(0.28 |
) |
$ |
0.28 |
|
$ |
0.01 |
$ |
(7.35 |
) |
$ |
7.30 |
|
$ |
(0.05 |
) |
||||||||
(1) |
Acquired intangible assets amortization expense |
|
5,495 |
|
|
4,065 |
|
||||||||||||||||||
|
Non-cash stock-based compensation expense |
|
804 |
|
|
524 |
|
||||||||||||||||||
|
Restructuring and other related costs |
|
67 |
|
|
191 |
|
||||||||||||||||||
|
Impairment charges |
|
2,141 |
|
|
5,256 |
|
||||||||||||||||||
|
|
8,507 |
|
|
10,036 |
|
|||||||||||||||||||
|
|||||||||||||||||||||||||
(2) |
Acquired intangible assets amortization expense |
|
2,205 |
|
|
2,162 |
|
||||||||||||||||||
|
Non-cash stock-based compensation expense |
|
7,154 |
|
|
4,352 |
|
||||||||||||||||||
|
|
- |
|
|
386,154 |
|
|||||||||||||||||||
|
Impairment of long-lived assets |
|
1,242 |
|
|
- |
|
||||||||||||||||||
|
Restructuring and other related costs |
|
210 |
|
|
34 |
|
||||||||||||||||||
|
Revaluation of investments |
|
2,025 |
|
|
- |
|
||||||||||||||||||
|
Contingent consideration |
|
197 |
|
|
- |
|
||||||||||||||||||
|
Legal and other expenses |
|
2,199 |
|
|
530 |
|
||||||||||||||||||
|
|
15,232 |
|
|
393,232 |
|
|||||||||||||||||||
|
|
23,739 |
|
|
403,268 |
|
|||||||||||||||||||
|
|||||||||||||||||||||||||
(3) |
Corresponding tax effect |
|
(376 |
) |
|
(1,296 |
) |
||||||||||||||||||
|
Equity method related amortization, divestments and impairments |
|
(4,771 |
) |
|
78 |
|
||||||||||||||||||
|
$ |
18,592 |
|
$ |
402,050 |
|
|||||||||||||||||||
(4) |
Weighted average number of ordinary shares outstanding- Diluted |
|
65,018 |
|
|
65,950 |
|
55,086 |
|
|
55,086 |
|
Nine Months Ended |
||||||||||||||||||||||||||
2021 |
|
Non-GAAP |
|
2021 |
|
2020 |
|
Non-GAAP |
|
2020 |
||||||||||||||||
GAAP |
|
Adjustments |
|
Non-GAAP |
|
GAAP |
|
Adjustments |
|
Non-GAAP |
||||||||||||||||
|
||||||||||||||||||||||||||
Gross profit (1) | $ |
187,035 |
|
$ |
22,192 |
|
$ |
209,227 |
|
$ |
153,375 |
|
$ |
24,062 |
|
$ |
177,437 |
|
||||||||
Operating income (loss) (1,2) | $ |
(63,001 |
) |
$ |
59,657 |
|
$ |
(3,344 |
) |
$ |
(453,468 |
) |
$ |
435,987 |
|
$ |
(17,481 |
) |
||||||||
Net income (loss) attributable to |
$ |
(57,146 |
) |
$ |
52,284 |
|
$ |
(4,862 |
) |
$ |
(454,751 |
) |
$ |
433,821 |
|
$ |
(20,930 |
) |
||||||||
Net income (loss) per diluted share attributable to |
$ |
(0.91 |
) |
$ |
0.83 |
|
$ |
(0.08 |
) |
$ |
(8.29 |
) |
$ |
7.91 |
|
$ |
(0.38 |
) |
||||||||
(1) |
Acquired intangible assets amortization expense |
|
16,368 |
|
|
12,196 |
|
|||||||||||||||||||
|
Non-cash stock-based compensation expense |
|
2,226 |
|
|
1,424 |
|
|||||||||||||||||||
|
Impairment charges |
|
2,141 |
|
|
5,256 |
|
|||||||||||||||||||
|
Restructuring and other related costs |
|
1,457 |
|
|
5,187 |
|
|||||||||||||||||||
|
|
22,192 |
|
|
24,062 |
|
||||||||||||||||||||
|
||||||||||||||||||||||||||
(2) |
Acquired intangible assets amortization expense |
|
6,598 |
|
|
6,430 |
|
|||||||||||||||||||
|
Non-cash stock-based compensation expense |
|
20,914 |
|
|
14,470 |
|
|||||||||||||||||||
|
|
- |
|
|
386,154 |
|
||||||||||||||||||||
|
Impairment of long-lived assets |
|
2,664 |
|
|
- |
|
|||||||||||||||||||
|
Restructuring and other related costs |
|
2,370 |
|
|
3,863 |
|
|||||||||||||||||||
|
Revaluation of investments |
|
556 |
|
|
- |
|
|||||||||||||||||||
|
Contingent consideration |
|
590 |
|
|
- |
|
|||||||||||||||||||
|
Legal and other expenses |
|
3,773 |
|
|
1,007 |
|
|||||||||||||||||||
|
|
37,465 |
|
|
411,925 |
|
||||||||||||||||||||
|
|
59,657 |
|
|
435,987 |
|
||||||||||||||||||||
|
||||||||||||||||||||||||||
(3) |
Corresponding tax effect |
|
(2,770 |
) |
|
(2,396 |
) |
|||||||||||||||||||
|
Equity method related amortization, divestments and impairments |
|
(4,603 |
) |
|
230 |
|
|||||||||||||||||||
|
$ |
52,284 |
|
$ |
433,821 |
|
||||||||||||||||||||
|
||||||||||||||||||||||||||
(4) |
Weighted average number of ordinary shares outstanding- Diluted |
|
62,888 |
|
|
62,888 |
|
|
54,851 |
|
|
54,851 |
|
|||||||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005134/en/
CCO, VP Investor Relations
Yonah.Lloyd@stratasys.com
Source:
FAQ
What were Stratasys's Q3 2021 earnings results?
How does Stratasys's Q3 2021 performance compare to Q3 2020?
What is the revenue outlook for Stratasys in Q4 2021?
What new contracts did Stratasys secure recently?